Hims & Hers Health (NYSE:HIMS), a direct-to-consumer telehealth platform offering prescription and non-prescription health products, closed Thursday at $23.84, down 7.88%. The stock fell as traders took profits after a sharp multi-day rally driven by its new Novo Nordisk partnership and a shift in its GLP-1 strategy, and investors are watching execution on its branded obesity drugs. Trading volume reached 68 million shares, coming in about 126% above its three-month average of 30 million shares.